Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin specific peptidase 17 like family member 19 (USP17L19)
- Target
- USP17L19
- Molecular classification
- Enzyme, Deubiquitinating enzyme (DUB), Cysteine-type endopeptidase
01
Overview
Ubiquitin specific peptidase 17 like family member 19 (USP17L19) is a member of the USP17 subfamily of deubiquitinating enzymes (DUBs), responsible for removing ubiquitin from protein substrates. These enzymes regulate protein turnover and stability, and USP17L19 is predicted to influence cell proliferation, cell cycle progression, apoptosis, and cell migration. The USP17 family is rapidly induced by chemokines and cytokines, participating downstream of receptor signaling, notably in GTPase-dependent cell motility and cytoskeletal rearrangement. USP17 family DUBs, including USP17L19, are considered druggable targets in cancer and inflammatory diseases due to their roles in cellular migration and proliferation. However, drug development and characterization of USP17L19-specific pharmacology remain at a preclinical stage.
- Other names
- Ubiquitin carboxyl-terminal hydrolase 17-like protein 19USP17L19U17LJ proteinD6RCP7 (UniProtKB/Swiss-Prot entry)HGNC:44447NCBI Gene: 100287404Ensembl: ENSG00000248920
02
Mechanism of action
Inhibition of USP17L19 would block deubiquitination of specific substrates, affecting cell cycle progression, migration, and possibly apoptotic regulation
03
Biological functions
Deubiquitination (removes ubiquitin conjugates from specific proteins)Regulation of apoptotic processRegulation of protein stabilityCell proliferationProgression through cell cycleApoptosisCell migrationResponse to viral infection
04
Disease associations
Cancer (regulation of cell migration, invasion, and cell cycle control)Inflammation (chemokine-induced migration in immune contexts)Potentially viral infection responseOther (cellular proliferation, apoptosis regulation)
05
Safety considerations
Potential effects on cell viability, cell cycle progression, immune cell migration, and apoptosis if targeted by drugsTherapeutic challenge: specific inhibition may disrupt processes like immune response and tissue homeostasis
06
Interacting drugs
No drugs currently documented to interact specifically with USP17L19. (USP17 family DUBs are considered emerging drug targets, but no approved inhibitors are listed for USP17L19)
07
Biomarkers
No clinically validated biomarkers for USP17L19 patient selection or monitoring as of 2025Expression or activity of USP17 family enzymes is under research in oncology contexts
Beyond the preview
Go deeper on Ubiquitin specific peptidase 17 like family member 19 (USP17L19).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ubiquitin specific peptidase 17 like family member 19 (USP17L19).